1. Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. PMID: 37861218.
   
   
2. de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS^G12C mutation: a randomised, open label, phase 3 trial. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. PMID: 36764316.
   
   
3. Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol. 2023 Mar;20(3):143-159. doi: 10.1038/s41571-022-00718-x. Epub 2023 Jan 13. PMID: 36639452.
   
   
4. Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. PMID: 36252599.
   
   
5. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: Lancet Oncol. 2021 Mar;22(3):e92. PMID: 33476593.
   
   
6. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. PMID: 33285097.

1. Sanz-Castillo B, Hurtado B, Vara-Ciruelos D, El Bakkali A, Hermida D, Salvador-Barbero B, Martínez-Alonso D, González-Martínez J, Santiveri C, Campos-Olivas R, Ximénez-Embún P, Muñoz J, Álvarez-Fernández M, Malumbres M. The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. EMBO J. 2023 Jan 16;42(2):e110833. doi: 10.15252/embj.2022110833. Epub 2022 Nov 10. PMID: 36354735; PMCID: PMC9841333.
   
   
2. Villarroya-Beltri C, Martins AFB, García A, Giménez D, Zarzuela E, Novo M, Del Álamo C, González-Martínez J, Bonel-Pérez GC, Díaz I, Guillamot M, Chiesa M, Losada A, Graña-Castro O, Rovira M, Muñoz J, Salazar-Roa M, Malumbres M. Mammalian CDC14 phosphatases control exit from stemness in pluripotent cells. EMBO J. 2023 Jan 4;42(1):e111251. doi: 10.15252/embj.2022111251. Epub 2022 Nov 3. PMID: 36326833; PMCID: PMC9811616.
   
   
3. Villarroya-Beltri C, Osorio A, Torres-Ruiz R, Gómez-Sánchez D, Trakala M, Sánchez-Belmonte A, Mercadillo F, Hurtado B, Pitarch B, Hernández-Núñez A, Gómez-Caturla A, Rueda D, Perea J, Rodríguez-Perales S, Malumbres M, Urioste M. Biallelic germline mutations in MAD1L1 induce a syndrome of aneuploidy with high tumor susceptibility. Sci Adv. 2022 Nov 4;8(44):eabq5914. doi: 10.1126/sciadv.abq5914. Epub 2022 Nov 2. PMID: 36322655; PMCID: PMC9629740.
   
   
4. Salvador-Barbero B, Alvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, Di Domenico T, Xie T, VanArsdale T, Shields DJ, Hidalgo M, Malumbres M. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020 Oct 12;38(4):584. doi: 10.1016/j.ccell.2020.09.012. Erratum for: Cancer Cell. 2020 Mar 16;37(3):340-353.e6. PMID: 33049208.
   
   
5. Salazar-Roa M, Trakala M, Álvarez-Fernández M, Valdés-Mora F, Zhong C, Muñoz J, Yu Y, Peters TJ, Graña-Castro O, Serrano R, Zapatero-Solana E, Abad M, Bueno MJ, Gómez de Cedrón M, Fernández-Piqueras J, Serrano M, Blasco MA, Wang DZ, Clark SJ, Izpisua-Belmonte JC, Ortega S, Malumbres M. Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells. EMBO J. 2020 Aug 17;39(16):e104324. doi: 10.15252/embj.2019104324. Epub 2020 Jul 2. PMID: 32614092; PMCID: PMC7429746.

1. Salmón M, Álvarez-Díaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, Fernández-García F, López-García A, Martín-Guijarro MC, Rodríguez-Perales S, Bousquet-Mur E, Morales-Cacho L, Mulero F, Al-Shahrour F, Martínez L, Domínguez O, Caleiras E, Ortega S, Guerra C, Musteanu M, Drosten M, Barbacid M. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. J Clin Invest. 2023 Apr 3;133(7):e164413. doi: 10.1172/JCI164413. PMID: 36928090; PMCID: PMC10065067.
   
   
2. Salmón M, Paniagua G, Lechuga CG, Fernández-García F, Zarzuela E, Álvarez-Díaz R, Musteanu M, Guerra C, Caleiras E, Muñoz J, Ortega S, Drosten M, Barbacid M. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):e2023112118. doi: 10.1073/pnas.2023112118. PMID: 34301865; PMCID: PMC8325162.
   
   
3. Sanclemente M, Nieto P, Garcia-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, Drosten M, Caleiras E, Martinez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. Cancer Cell. 2021 Mar 8;39(3):294-296. doi: 10.1016/j.ccell.2021.01.008. Epub 2021 Jan 28. PMID: 33513349.

This article was recommended in Faculty Opinions as being of special significance in its field

4. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10. PMID: 32913049; PMCID: PMC7533841.
   
   
5. Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27. PMID: 29395869.

Commentaries for this article appeared in:

Cancer Cell: F. McCormick: c-Raf in KRas Mutant Cancers: A Moving Target. Cancer Cell, 33: 158-159

Science Translational Medicine: A. Lujambio A new hope for KRAS mutant cancers. Sci Transl. Medicine, 10: eaas8964  http://stm.sciencemag.org/content/10/429/eaas8964.full

This article was also recommended in F1000Prime as being of special significance in its field

1. Hernandez S, Conde E, Molero A, Suarez-Gauthier A, Martinez R, Alonso M, Plaza C, Camacho C, Chantada D, Juaneda-Magdalena L, Garcia-Toro E, Saiz-Lopez P, Rojo F, Abad M, Boni V, Del Carmen S, Regojo RM, Sanchez-Frias ME, Teixido C, Paz-Ares L, Lopez-Rios F. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. Arch Pathol Lab Med. 2023 Jun 1. doi: 10.5858/arpa.2022-0443-OA. Epub ahead of print. PMID: 37270803.
   
   
2. Quintanal-Villalonga Á, Ferrer I, Guruceaga E, Cirauqui C, Marrugal Á, Ojeda L, García S, Zugazagoitia J, Muñoz-Galván S, Lopez-Rios F, Montuenga L, Vicent S, Molina-Pinelo S, Carnero A, Paz-Ares L. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine. 2020 Mar;53:102683. doi: 10.1016/j.ebiom.2020.102683. Epub 2020 Feb 27. PMID: 32114392; PMCID: PMC7047190.
   
   
3. Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. J Thorac Oncol. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. Epub 2019 Jul 23. PMID: 31349061.
   
   
4. Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal Á, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer. 2019 May;131:112-121. doi: 10.1016/j.lungcan.2019.02.007. Epub 2019 Feb 8. PMID: 31027687.
   
   
5. Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Márquez L, Marrugal Á, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. J Thorac Oncol. 2019 Apr;14(4):641-655. doi: 10.1016/j.jtho.2018.12.021. Epub 2019 Jan 9. PMID: 30639621.

1. Escobar JE, Molina J, Gil-Santos E, Ruz JJ, Malvar Ó, Kosaka PM, Tamayo J, San Paulo Á, Calleja M. Nanomechanical Sensing for Mass Flow Control in Nanowire-Based Open Nanofluidic Systems. ACS Nano. 2023 Nov 14;17(21):21044-21055. doi: 10.1021/acsnano.3c04020. Epub 2023 Oct 30. PMID: 37903505; PMCID: PMC10655260.
   
   
2. Sanz-Jiménez A, Ruz JJ, Gil-Santos E, Malvar O, García-López S, Kosaka PM, Cano Á, Calleja M, Tamayo J. Square Membrane Resonators Supporting Degenerate Modes of Vibration for High-Throughput Mass Spectrometry of Single Bacterial Cells. ACS Sens. 2023 May 26;8(5):2060-2067. doi: 10.1021/acssensors.3c00338. Epub 2023 Apr 30. PMID: 37122237; PMCID: PMC10226162.
   
   
3. Sanz-Jiménez A, Malvar O, Ruz JJ, García-López S, Kosaka PM, Gil-Santos E, Cano Á, Papanastasiou D, Kounadis D, Mingorance J, Paulo ÁS, Calleja M, Tamayo J. High-throughput determination of dry mass of single bacterial cells by ultrathin membrane resonators. Commun Biol. 2022 Nov 11;5(1):1227. doi: 10.1038/s42003-022-04147-5. PMID: 36369276; PMCID: PMC9651879.
   
   
4. Molina J, Escobar JE, Ramos D, Gil-Santos E, Ruz JJ, Tamayo J, San Paulo Á, Calleja M. High Dynamic Range Nanowire Resonators. Nano Lett. 2021 Aug 11;21(15):6617-6624. doi: 10.1021/acs.nanolett.1c02056. Epub 2021 Jul 21. PMID: 34288677; PMCID: PMC8361434.
   
   
5. Yubero ML, Kosaka PM, San Paulo Á, Malumbres M, Calleja M, Tamayo J. Effects of energy metabolism on the mechanical properties of breast cancer cells. Commun Biol. 2020 Oct 20;3(1):590. doi: 10.1038/s42003-020-01330-4. PMID: 33082491; PMCID: PMC7576174.